Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskNeutral

NEUROCRINE BIOSCIENCES, INC.

A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.

www.neurocrine.com
Filed: Sep 25, 2026San Diego, CaliforniaCIK: 0000914475Biotechnology
Full company profileView on SEC.gov

The seat is still open. No replacement has been named 14 days after this filing.

See every company with multiple executive changes →

AI Executive Summary

AI-powered analysis of 8-K filing content

Neurocrine Biosciences announced the mutual termination of Chief Medical Officer Dr. Sanjay Keswani effective September 25, 2026, with Dr. Eiry W. Roberts, M.D. appointed as successor effective September 28, 2026. The company characterized this as a strategic leadership change to align medical direction with evolving business objectives.

Key Takeaways

Dr. Sanjay Keswani terminated as Chief Medical Officer effective immediately on September 25, 2026

Dr. Eiry W. Roberts, M.D. appointed as successor with effective date of September 28, 2026

2 more takeaways

Filing Overview

Form Type8-K
Filing DateSep 25, 2026
Item5.02
CategoryExecutive Change
CIK0000914475
Accession #0000914475-26-000045
Risk LevelMEDIUM
SentimentNeutral
Signalinformational
Topics
executive departureleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

NEUROCRINE BIOSCIENCES, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.